Patents by Inventor Anna Offersgaard

Anna Offersgaard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20260263580
    Abstract: The present invention relates to nucleic acid sequences that encode high-yield hepatitis C viruses (HCV) of genotype 1a, 2a or 3a that are useful in the fundamental research of HCV as well as in the search of antivirals and vaccines against HCV. In particular, the present invention relates to nucleic acid sequences that comprise HCV, which are capable of expressing the virus when transfected into cells and are capable of replication or infectivity in cultured cells as well as being functional as a vaccine.
    Type: Application
    Filed: June 30, 2023
    Publication date: September 10, 2026
    Inventors: Garazi Pena Alzua, Anne Finne Pihl, Anna Offersgaard, Ulrik Fahnøe, Jens Bukh, Judith Margarete Gottwein
  • Patent number: 12497598
    Abstract: The present invention relates to a method of purifying whole HCV particles, the method comprising the steps of a) providing a cell culture supernatant comprising virus particles, b) purification and/or concentration of the cell culture supernatant, c) purification and/or concentration of the product of above step b) using steric exclusion chromatography (SXC) at alkaline pH in the range of 8-10, d) purification and/or concentration of the product of the above step c) using sulphated cellulose membrane absorbers (SCMA), e) obtaining whole virus particles.
    Type: Grant
    Filed: July 12, 2021
    Date of Patent: December 16, 2025
    Assignee: Hvidovre Hospital
    Inventors: Judith Margarete Gottwein, Jens Bukh, Anna Offersgaard, Anne Finne Pihl, Michael Wolff, Keven Lothert
  • Publication number: 20230272350
    Abstract: The present invention relates to a method of purifying whole HCV particles, the method comprising the steps of a) providing a cell culture supernatant comprising virus particles, b) purification and/or concentration of the cell culture supernatant, c) purification and/or concentration of the product of above step b) using steric exclusion chromatography (SXC) at alkaline pH in the range of 8-10, d) purification and/or concentration of the product of above step c) using sulphated cellulose membrane absorbers (SCMA), e) obtaining purified whole virus particles.
    Type: Application
    Filed: July 12, 2021
    Publication date: August 31, 2023
    Inventors: Judith Margarete Gottwein, Jens Bukh, Anna Offersgaard, Anne Finne Pihl, Michael Wolff, Keven Lothert